


| DESCRIPTION               |   |
|---------------------------|---|
| <b>Species Reactivity</b> | Feline  |
| <b>Specificity</b>        | Detects feline IL-4 in direct ELISAs and Western blots. In direct ELISAs, approximately 15% cross-reactivity with recombinant canine IL-4, recombinant cotton rat IL-4, recombinant human IL-4, recombinant mouse IL-4, recombinant porcine IL-4, and recombinant rat IL-4 is observed. |
| <b>Source</b>             | Polyclonal Goat IgG   |
| <b>Purification</b>       | Antigen Affinity-purified   |
| <b>Immunogen</b>          | <i>E. coli</i> -derived recombinant feline IL-4<br>Gln24-His133<br>Accession # P55030   |
| <b>Endotoxin Level</b>    | <0.10 EU per 1 µg of the antibody by the LAL method.  |
| <b>Formulation</b>        | Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.<br>*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.   |

| APPLICATIONS   |   |  |
|--|---|--|
| <b>Please Note:</b> Optimal dilutions should be determined by each laboratory for each application. <i>General Protocols</i> are available in the <i>Technical Information</i> section on our website. |   |  |
|  | <b>Recommended Concentration</b>  | <b>Sample</b>                              |
| <b>Western Blot</b>  | 0.1 µg/mL   | Recombinant Feline IL-4 (Catalog # 984-FL) |
| <b>Neutralization</b>  | Measured by its ability to neutralize IL-4-induced proliferation in the TF-1 human erythroleukemic cell line. Kitamura, T. <i>et al.</i> (1989) <i>J. Cell Physiol.</i> <b>140</b> :323. The Neutralization Dose (ND <sub>50</sub> ) is typically 2-8 µg/mL in the presence of 100 ng/mL Recombinant Feline IL-4. |  |



| PREPARATION AND STORAGE        |  |
|--------------------------------|--|
| <b>Reconstitution</b>          | Reconstitute at 0.2 mg/mL in sterile PBS.  |
| <b>Shipping</b>                | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.<br>*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C   |
| <b>Stability &amp; Storage</b> | <b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul> |

**BACKGROUND**

Interleukin-4 (IL-4), also known as B cell-stimulatory factor-1, is a monomeric, approximately 13-18 kDa Th2 cytokine that shows pleiotropic effects during immune responses (1-3). It is a glycosylated polypeptide that contains three intrachain disulfide bridges and adopts a bundled four  $\alpha$ -helix structure (4). Feline IL-4 is synthesized with a 24 amino acid (aa) signal sequence. Mature feline IL-4 shares 81%, 64%, 49%, 40%, and 40% aa sequence identity with canine, bovine, human, mouse, and rat IL-4, respectively. Human IL-4 is active on feline dendritic cells (5). IL-4 exerts its effects through two receptor complexes (6, 7). The type I receptor, which is expressed on hematopoietic cells, is a heterodimer of the ligand binding IL-4 R $\alpha$  and the common  $\gamma$  chain (a shared subunit of the receptors for IL-2, -7, -9, -15, and -21). The type II receptor on nonhematopoietic cells consists of IL-4 R $\alpha$  and IL-13 R $\alpha$ 1. The type II receptor also transduces IL-13 mediated signals. IL-4 is primarily expressed by Th2-biased CD4<sup>+</sup> T cells, mast cells, basophils, and eosinophils (1, 2). It promotes cell proliferation, survival, and immunoglobulin class switch to IgE in B cells, acquisition of the Th2 phenotype by naïve CD4<sup>+</sup> T cells, priming and chemotaxis of mast cells, eosinophils, and basophils, and the proliferation and activation of epithelial cells (8-11). IL-4 plays a dominant role in the development of allergic inflammation and asthma (10, 12).

**References:**

1. Benczik, M. and S.L. Gaffen (2004) *Immunol. Invest.* **33**:109.
2. Chomarat, P. and J. Banchereau (1998) *Int. Rev. Immunol.* **17**:1.
3. SwissProt # P55030.
4. Redfield, C. *et al.* (1991) *Biochemistry* **30**:11029.
5. Sprague, W.S. *et al.* (2005) *J. Comp. Pathol.* **133**:136.
6. Mueller, T.D. *et al.* (2002) *Biochim. Biophys. Acta* **1592**:237.
7. Nelms, K. *et al.* (1999) *Annu. Rev. Immunol.* **17**:701.
8. Paludan, S.R. (1998) *Scand. J. Immunol.* **48**:459.
9. Corthay, A. (2006) *Scand. J. Immunol.* **64**:93.
10. Ryan, J.J. *et al.* (2007) *Crit. Rev. Immunol.* **27**:15.
11. Grone, A. (2002) *Vet. Immunol. Immunopathol.* **88**:1.
12. Rosenberg, H.F. *et al.* (2007) *J. Allergy Clin. Immunol.* **119**:1303.